{"nct_id":"NCT07005102","title":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-08-03","start_date_type":"ACTUAL","primary_completion_date":"2031-12","primary_completion_date_type":"ESTIMATED","completion_date":"2031-12","completion_date_type":"ESTIMATED","phases":["PHASE2","PHASE3"],"tickers":["ABBV"]}